The correlation of age and body mass index with the level of both protease MMP3 and anti-protease TIMP-1 among Indonesian patients with chronic obstructive pulmonary disease: a preliminary findings

Mulyadi1, Sunnati2, Mulkan Azhary1, Faisal Yunus3 and Fariz Nurwidya3*

Abstract
Objectives: Individuals with chronic obstructive pulmonary disease (COPD) are usually > 50 years of age and have a low body mass index (BMI). An imbalance between matrix metalloproteinases (MMPs), including MMP-3, and tissue inhibitor of metalloproteinase 1 (TIMP-1), play a role in tissue degradation of lung extracellular matrix among COPD individuals. The purpose of the present study was to correlate age and/or BMI with salivary levels of MMP-3 and TIMP-1 among Indonesian subjects with COPD.

Results: Thirty COPD patients were recruited to undergo thorough physical assessment and saliva collection for evaluating TIMP-1 and MMP-3 levels using commercially available kits enzyme-linked immunosorbent assay method. The mean (standard deviation) participant age and BMI were 60.5 (8.13) years, and 23.1 (4.75) kg/m², respectively. Furthermore, the mean (standard deviation) of TIMP-1 and MMP3 levels were 23.99 (6.85) ng/mL and 1.81 (1.167) μM, respectively. Age was negatively correlated with MMP-3 (P < 0.05), but not with TIMP-1 levels. Age and BMI were not correlated with TIMP-1 level (P > 0.05). Collectively, this study demonstrated that age has a negative correlation with the protease marker (i.e. MMP-3), but not the anti-protease marker (TIMP-1). BMI was not correlated with either protease/anti-protease marker among Indonesian subjects with COPD.

Keywords: Age, BMI, Salivary MMP-3, Salivary TIMP-1

Introduction
The proportion of active smokers with chronic obstructive pulmonary disease (COPD) is estimated to be 10–15% [1, 2]. COPD is characterized by partially irreversible airflow limitation, emphysema, reduced diameter of the small airways, and chronic bronchitis [3]. Smoking cessation may improve symptoms; however, the inflammatory process within the airways and in the lung parenchyma will persist [4].

Matrix metalloproteinases (MMPs) are counteracted by tissue inhibitor of matrix metalloproteinases (TIMPs), which results in reduced extracellular matrix (ECM) breakdown. The balance between MMPs and TIMPs is essential in maintaining the integrity of normal body tissues. An imbalance in the ratio of MMPs and TIMPs may manifest as numerous pathological conditions including rheumatoid arthritis, cancer, and periodontitis [5].

In the field of periodontology, smoking has been associated with an increased incidence and severity of various periodontal diseases [6]. Inflammation within the oral cavity and in the airway can be assessed using
biomarkers. In the case of periodontitis, various tests can be performed using samples obtained from saliva and gingival crevicular fluid [7, 8].

TIMP-1 inhibits active MMPs, including MMP-1, MMP-3, and MMP-9. It has been reported that changes in MMP-1 poorly correlated with disease intensity and progression in COPD [9]. TIMP-1 binds to pro-MMP-9 to prevent the activation of pro-MMP-9. However, neutrophil elastase acts by dissociating the binding of TIMP-1 to pro-MMP-9, which allows MMP-3 to activate pro-MMP-9 to become MMP-9 [10]. Our previous study revealed that salivary MMP-9 was not correlated with lung function in COPD patients, which prompted us to confirm whether salivary MMP-3 could be a viable biomarker associated with age and body mass index (BMI) at the onset of COPD [11]. This study aimed to investigate possible correlations between degenerative variables, such as age and BMI, and the level of salivary MMP-3 and TIMP-1 in Indonesian patients with COPD.

**Main text**

**Methods**

This study recruited 30 consecutive smokers with COPD who visited the pulmonary outpatient clinic of the Dr. Zainoel Abidin General Hospital, located in Banda Aceh, Indonesia. The inclusion criteria were a diagnosis of COPD; current smoker; male sex; > 50 years of age; and 20 pack-years of cigarette consumption. Diagnosis of COPD was established according to spirometry results (i.e., forced expiratory volume in 1 s/forced vital capacity ratio < 70% according to the 2017 Global Initiative for Chronic Obstructive Lung Disease guidelines [12]. Patients with respiratory or oral infections, or malignancy, were excluded. This study was approved by the Ethics Committee of the Faculty of Medicine, University of Syiah Kuala, Banda Aceh, Indonesia (Ethical Clearance No. 197/KE/FFK/2013). All participants were required to provide informed consent before undergoing the research procedures.

Saliva was collected into sterile pots and stored in a −80 °C freezer for analysis of TIMP-1 and MMP-3 using a human TIMP-1 quantikine ELISA kit (R&D Systems, Minneapolis, MN, USA) and Sensolyte 520 Generic MMP fluorimetric assay kit (AnaSpec, Fremont, CA, USA), respectively, according to manufacturer’s protocols.

Data are presented as mean and standard deviation (SD). Pearson’s correlation coefficient was used to determine the correlation between variables. The data were analyzed using SPSS version 15.0 (IBM Corporation, Chicago, IL, USA) for Windows (Microsoft Corporation, Redmond, WA, USA), and $P<0.05$ was considered to be statistically significant.

**Results**

The mean (SD) age of the subjects was 60.5 (8.13) years, and the mean (SD) BMI was 23.1 (4.75) kg/m². The mean (SD) level of salivary TIMP-1 was 23.99 (6.85) ng/mL, and the mean (SD) activity of salivary MMP-3 was 1.81 (1.167) μM (Table 1).

Next, the authors analyzed the correlation between age and BMI with MMP-3 activity using Pearson’s correlation coefficient. Age was significantly correlated with the salivary MMP-3 levels ($P=0.002$), however BMI was not correlated with MMP-3 activity (Table 2).

Finally, the authors investigated possible relationships between BMI and anti-protease (i.e., TIMP-1) level using Pearson’s correlation coefficient, and found that BMI was not correlated with salivary TIMP-1 levels (Table 3).

**Discussion**

Identification of protease and anti-protease biomarkers in COPD patients using non-invasively obtained fluid samples are under intensive investigation. It has been reported that TIMP-1 levels in lung tissue increase in response to higher activities of lung parenchymal MMP-3 [13]. In periodontitis, the development of attachment loss will be inhibited by TIMP-1 to prevent further potential tissue damage. These are considered to be the natural responses of anti-proteases against increased protease activity [14].

MMPs are divided into several subgroups according to their primary substrate, such as collagenases (MMP-1 and MMP-13) degrading the interstitial collagens, and gelatinases (MMP-2 and MMP-9) that degrade basal membrane components such as fibronectin and elastin [15]. As an “anti-protease”, TIMP-1 acts in response to increased activities of MMP-3 and MMP-9, and acts to prevent degradation of ECM in tissues. If there is reduced ability of TIMP to act against exogenous and endogenous MMP, this will result in the prolonged and increased activity of MMP-3 and MMP-9, which results in ECM damage [16, 17].

MMP-3 is a broad-spectrum MMP that functions by activating latent MMPs including pro-MMP-1, -8 and -9. The overall cascade of tissue degradation occurs due to the involvement of the regulatory effects of MMP-3.

**Table 1** Subject characteristics

| Variable               | Mean (SD)   |
|------------------------|-------------|
| Age (years)            | 60.5 (8.13) |
| Body mass index (kg/m²)| 23.1 (4.75) |
| MMP-3 activity (μM)    | 1.81 (1.167) |
| TIMP-1 level (ng/mL)   | 23.99 (6.85) |

*MMP-3 matrix metalloproteinase-3, TIMP-1 tissue inhibitor of metalloproteinase 1*
Table 2 Correlation between individual characteristics and MMP-3 activity

| Variable       | MMP-3 activity |
|----------------|----------------|
|                | R   | P value |
| Age            | -0.42| 0.02  |
| Body mass index| -0.01| 0.97  |

Table 3 Correlation between age and body mass index and TIMP-1 level

| Variable       | TIMP-1 |
|----------------|--------|
|                | R   | P value |
| Age            | <0.001| 0.99  |
| Body mass index| 0.25 | 0.19  |

both physiologically and pathologically. The expression of MMP-3 and increased amounts of MMP-3 messenger RNA in periodontal lesions have been reported in previous studies, which concluded that MMP-3 may be marker for assessing the tissue degradation process [5].

There is an increased risk for periodontitis among smokers with COPD. In contrast, smokers without COPD exhibit higher mean TIMP-1 levels in response to increased activities of MMP-3 and MMP-9. Verstappen et al. [18] observed increased levels of TIMP-1 in the healthy periodontium compared with inflamed periodontium, which represents a homeostatic mechanism to sustain balances between proteases and anti-proteases to prevent ECM damage.

TIMP-1 is crucial to the balance of increased MMP-9 activity, and cigarette smoke exposure among smokers without COPD could be implicated in the activation of several pro-inflammatory signal pathways, including oxidative stress, pro-inflammatory cells, and alveolar macrophages, which results in the activation of several proteases, especially MMP-9. An in vivo study reported that TIMP-1 was highly expressed in respiratory epithelial cells that had been exposed to chronic inflammation. The epithelial tissue expressed TIMP-1 in response to the activity of MMPs [19]. Furthermore, in a study by Higashimoto et al. [20], involving smokers without COPD who consumed the same number of cigarettes as smokers with COPD, suggested a similar risk for continuous airway inflammation between both groups and due to persistent cigarette smoke exposure.

Fujita [21] found that the activities of both MMP-9 and TIMP-1 following lung injury in COPD led to either recovery or degradation of ECM. Among smokers without COPD, the activities of MMP-9 and TIMP-1 will result in recovery and resolution; meanwhile, in smokers with COPD, this will result in ECM destruction and emphysema [21].

In conclusion, our preliminary findings suggest that salivary TIMP-1 is not a suitable biomarker in Indonesian subjects with COPD. There was, however, a significant negative correlation between age and the level of MMP-3 activity. Further study with a more heterogeneous population is required to clarify the precise role of TIMP-1 as a possible biomarker of anti-protease activity in the lung.

Limitations
The current study involved a small number of subjects; therefore, the findings may not reflect the true correlation that may exist between protease/anti-protease imbalances and age and BMI. Furthermore, the study was conducted in a single-institution and involved only male subjects, which, considering the heterogeneity of the Indonesian population, may restrict the generalizability of the findings.

Abbreviations
BMI: body mass index; COPD: chronic obstructive pulmonary disease; ECM: extracellular matrix; MMP: matrix metalloproteinase; TIMP: tissue inhibitor of metalloproteinase.

Authors’ contributions
M contributed to conceptualization, methodology, data collection, formal analysis, validation, writing review, and editing. S contributed to conceptualization, methodology, formal analysis, validation. MA contributed to methodology, formal analysis, investigation. FY contributed to conceptualization, methodology, formal analysis, validation, manuscript editing. FN contributed to conceptualization, formal analysis, validation, manuscript writing. All authors read and approved of the final manuscript.

Author details
1 Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia. 2 Department of Periodontology, Faculty of Dentistry, Universitas Syiah Kuala, Banda Aceh, Indonesia. 3 Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Persahabatan Hospital, Jalan Persahabatan Raya No.1, Rawamangun, Jakarta 13230, Indonesia.

Acknowledgements
The authors acknowledge the Indonesian Ministry of Research, Technology and Higher Education, who supported this study by providing the Fundamental Research Grant in 2015.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The data set supporting the conclusions of this article is not included to protect patient confidentiality. The datasets are not deposited in publicly accessible repositories due to internal institutional policy. However, the data set can be obtained from the authors upon reasonable request.

Consent to publish
Not applicable.
The study was granted ethics clearance from the Ethics Committee of Faculty of Medicine, University of Syiah Kuala, Banda Aceh, Indonesia (Ethical Clearance No. 197/KE/FK/2013). All respondents were required to provide written informed consent before undergoing research procedures.

Funding
Fundamental Research Grant from the Indonesian Ministry of Research, Technology and Higher Education.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 11 May 2018 Accepted: 1 August 2018
Published online: 02 August 2018

References
1. Zeng XT, Tu ML, Liu DY, Zheng D, Zhang J, et al. Periodontal disease and risk of chronic obstructive pulmonary disease: a meta-analysis of observational studies. PLoS ONE. 2012;7(10):e46508. https://doi.org/10.1371/journal.pone.0046508.
2. Tzortzaki EG, Tsoumakidou M, Makris D, Siafakas NM. Laboratory markers for COPD in “susceptible” smokers. Clin Chim Acta. 2006;364(1–2):124–38. https://doi.org/10.1016/j.cca.2005.06.008.
3. Motz GT, Eppert BL, Sun G, Wesselkamper SC, Linke MJ, Deka R, et al. Persistence of lung CDB T cell oligoclonal expansions upon smoking cessation in a mouse model of cigarette smoke-induced emphysema. J Immunol. 2008;181(11):8036–43. https://doi.org/10.4049/jimmunol.181.11.8036.
4. Lapperre TS, Sont JK, Schadewijk AV, Gosman MME, Postma DS, Bajema IM, et al. Smoking cessation and bronchial epithelial remodelling in COPD: a cross-sectional study. Respir Res. 2007;8(85):1–9. https://doi.org/10.1186/1465-9921-8-85.
5. Kumar M, Phougat N, Ruhil S, Balhara M, Chhillar AK. Genomics of chronic obstructive pulmonary disease (COPD); exploring the SNPs of protease–antiprotease pathway. Curr Genomics. 2013;14:204–13. https://doi.org/10.2174/1389202911314030006.
6. Peyvâ A, Obradović R, Krešić L, Kožović D. Smoking and periodontal disease: a review. Med Biol. 2007;14(2):53–9.
7. Rai B, Kaur J, Jain R, Anand SC. Levels of gingival crevicular metalloproteinases-8 and -9 in periodontitis. Saudi Dent J. 2010;22(3):129–31.
8. Kaya FA, Arslan SG, Kaya CA, Arslan H, Hamamci O. The gingival crevicular fluid levels of IL-1β, IL-6 and TNF-α in late adult rats. Int Dent Res. 2011;1:7–12. https://doi.org/10.5577/idntdents2011.1.vol1.no1.2.
9. D’Armiento JM, Goldklarg MP, Hardigan AA, Geraghty P, Roth MD, Connet JE, et al. Increased matrix metalloproteinase (MMPs) levels do not predict disease severity or progression in emphysema. PLoS ONE. 2013;8(2):e56352. https://doi.org/10.1371/journal.pone.0056352.
10. Palosaari H, Pennington CJ, Larmas M, Edwards DR, Tjaderhane L, Salo T. Expression profile of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in mature human odontoblast and pulp tissue. Eur J Oral Sci. 2003;11(2):117–27. https://doi.org/10.1034/j.1600-0722.2003.00026.x.
11. Mulyadi, Sunnati, Azhary M. The Correlation between pulmonary function tests and the salivary MMP-9 activity among chronic obstructive pulmonary disease (COPD) patients. Proc Chem. 2016;18:194–8. https://doi.org/10.1016/j.proche.2016.01.030.
12. Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. 2017. http://goldcopd.org. Accessed 20 Dec 2017.
13. Usher AKH, Stockley RA. The link between chronic periodontitis and COPD: a common role for the neutrophil. BMC Med. 2013;11(1):1–11. https://doi.org/10.1186/1741-7015-11-241.
14. Reddy NR, Deepa A, Madhu-Babu DSM, Chandra NS, Subba-Reddy CV, Kumar AK. Estimation of tissue inhibitor of matrix metalloproteinase-1 levels in gingival crevicular fluid in periodontal health, disease and after treatment. J Indian Soc Periodontol. 2014;18(3):301–5. https://doi.org/10.4103/0972-124X.106907.
15. Kumar PM, Reddy NR, Deepa A, Babu DSM, Kumar AK, Chavan V. Comparision of matrix metalloproteinase-3 and tissue inhibitor of matrix metalloproteinase-1 levels in gingival crevicular fluid in periodontal health, disease and after treatment: a clinico biochemical study. Dent Res J. 2013;10(4):434–9. http://drj.mui.ac.ir/index.php/drj/article/view/1464.
16. Owen CA, Hu Z, Barrick B, Shapiro SD. Inducible expression of tissue inhibitor of metalloproteinases-resistant matrix metalloproteinase-9 on the cell surface of neutrophils. Am J Respir Cell Mol Biol. 2003;29:283–94. https://doi.org/10.1165/rcmb.2003-0034OC.
17. Franco C, Patricia HR, Timo S, Claudia B, Marcela H. Matrix metalloproteinases as regulators of periodontal inflammation. Int J Mol Sci. 2017. https://doi.org/10.3390/ijms18020440.
18. Verstappen J, Von-den Hoff JW. Tissue inhibitors of metalloproteinases (TIMPs): their biological functions and involvement in oral diseases. J Dent Res. 2006;85:1074. https://doi.org/10.1177/0903990105051330.
19. Thorley AJ, Tetley TD. Pulmonary epithelium, cigarette smoke, and chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2007;2(4):409–28. https://www.dovepress.com/articles.php?artic le_id=537.
20. Hijashimoto Y, Yamagata Y, Iwata T, Okada M, Ishiguchi T, Sato H, et al. Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients. Eur Respir J. 2005;25:885–90. https://doi.org/10.1183/09031936.05.0002904.
21. Fujiya M. The role of MMPs in the progression of chronic lung inflammatory diseases. In: Ong KC (ed) Lung Inflammation, IntechOpen. 2014. https://doi.org/10.5772/57391. https://www.intechopen.com/books/lung-inflammation/the-role-of-mmps-in-the-progression-of-chronic-lung-inflammatory-diseases. Accessed 10 May 2018.